In Silico Design of a Novel Chimeric DT380-CD19 Recombinant Immunotoxin for Targeting Human B-Cell Lymphoma

Mohammadbagher, Davood; Noofeli, Mojtaba; Tabatabaei, Mohammad; Esmaelizad, Majid; Yektaseresht, Azadeh

doi:10.66224/ari.2026.372586.4107

In Silico Design of a Novel Chimeric DT380-CD19 Recombinant Immunotoxin for Targeting Human B-Cell Lymphoma

Articles in Press

Document Type : Original Articles

Authors

¹ Department of Pathobiology, Faculty of Veterinary Medicine, Shiraz University, Shiraz, Iran.

² Razi vaccine & serum research institute,

³ Department of Pathobiology, School of Veterinary Medicine, Shiraz University, Shiraz, Iran

⁴ Scinetific member and Head of Central Lab., Razi vaccine & serum research institute

10.66224/ari.2026.372586.4107

Abstract

Introduction: Cancer remains a major global health challenge, with high rates of morbidity and mortality. Traditional cancer treatments often cause adverse side effects due to their non-specific nature, leading to the exploration of targeted therapies, such as immunotoxins. Despite their potential, these therapies face hurdles, including the immunogenicity, off-target toxicity and low effectiveness. This research aims to explore a novel immunotoxin with reduced immunogenicity, improved safety and efficacy.
Materials and Methods: Through a comprehensive bioinformatics analysis, this study mainly evaluates the immunogenicity and docking profile of the novel recombinant immunotoxin. The designed immunotoxin created by combining the shortest truncated form of diphtheria toxin (consisting of 380 amino acids) with a single-chain variable fragment monoclonal antibody synthesized in E. coli system for specifically targeting the human CD19 antigen.
Results: In silico analyses show that the newly designed immunotoxin has acceptable immunogenicity and an improved targeting profile compared to existing versions and other B-cell malignancy immonotheraputics. This suggests its potential as a more effective and safer option for targeted therapy
Conclusion: The findings declare DT380-CD19 immunotoxin potential, as a more effective and safer option for B-cell malignancy targeted therapy than former theraputics. The research underscores the necessity of integrating both computational and experimental approaches to refine immunosuppressive techniques without compromising the therapeutic effectiveness of immunotoxin therapies, ultimately striving to improve patient outcomes in cancer treatment.

Keywords